Candriam Luxembourg S.C.A. Has $845,000 Stake in Zogenix Inc. (ZGNX)
Candriam Luxembourg S.C.A. maintained its stake in Zogenix Inc. (NASDAQ:ZGNX) during the second quarter, Holdings Channel reports. The institutional investor owned 105,000 shares of the company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in Zogenix were worth $845,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in ZGNX. State Street Corp boosted its position in shares of Zogenix by 4.2% in the first quarter. State Street Corp now owns 383,552 shares of the company’s stock valued at $3,546,000 after buying an additional 15,446 shares during the last quarter. Opaleye Management Inc. purchased a new position in shares of Zogenix during the first quarter valued at about $2,218,000. Landscape Capital Management L.L.C. purchased a new position in shares of Zogenix during the first quarter valued at about $1,439,000. Metropolitan Life Insurance Co. NY boosted its position in shares of Zogenix by 15.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 19,892 shares of the company’s stock valued at $184,000 after buying an additional 2,671 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Zogenix by 11.7% in the first quarter. Geode Capital Management LLC now owns 153,464 shares of the company’s stock valued at $1,418,000 after buying an additional 16,093 shares during the last quarter. Institutional investors own 84.91% of the company’s stock.
Shares of Zogenix Inc. (NASDAQ:ZGNX) traded down 2.68% on Friday, reaching $10.18. The company had a trading volume of 135,831 shares. The firm’s market capitalization is $252.36 million. The company’s 50-day moving average price is $9.66 and its 200 day moving average price is $9.52. Zogenix Inc. has a 52 week low of $7.33 and a 52 week high of $16.56.
Zogenix (NASDAQ:ZGNX) last released its earnings results on Tuesday, August 9th. The company reported ($0.76) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.05. Zogenix had a negative return on equity of 33.62% and a negative net margin of 192.64%. The firm earned $2.10 million during the quarter, compared to analysts’ expectations of $5.36 million. During the same period in the previous year, the firm posted ($3.78) EPS. Zogenix’s revenue for the quarter was down 71.6% on a year-over-year basis. On average, analysts expect that Zogenix Inc. will post ($3.24) EPS for the current year.
Several brokerages have recently issued reports on ZGNX. Leerink Swann restated an “outperform” rating and issued a $17.00 price objective on shares of Zogenix in a research note on Tuesday. Brean Capital restated a “buy” rating and issued a $28.00 price objective on shares of Zogenix in a research note on Wednesday, September 21st. Finally, Zacks Investment Research upgraded Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, August 13th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Zogenix presently has an average rating of “Buy” and an average price target of $20.50.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.
Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix Inc. (NASDAQ:ZGNX).
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.